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ARTICLE
Folliculin regulates mTORC1/2 and WNT pathways
in early human pluripotency
J. Mathieu1,2,3, D. Detraux1,2,8, D. Kuppers4, Y. Wang2,5, C. Cavanaugh2,3, S. Sidhu1,2, S. Levy1,2,
A.M. Robitaille2,6, A. Ferreccio1,2, T. Bottorff1,2, A. McAlister1,2, L. Somasundaram1,2, F. Artoni1,2, S. Battle2,7,
R.D. Hawkins2,7, R.T. Moon2,6, C.B. Ware2,3, P.J. Paddison2,4 & H. Ruohola-Baker 1,2
To reveal how cells exit human pluripotency, we designed a CRISPR-Cas9 screen exploiting
the metabolic and epigenetic differences between naïve and primed pluripotent cells. We
identify the tumor suppressor, Folliculin(FLCN) as a critical gene required for the exit from
human pluripotency. Here we show that FLCN Knock-out (KO) hESCs maintain the naïve
pluripotent state but cannot exit the state since the critical transcription factor TFE3 remains
active in the nucleus. TFE3 targets up-regulated in FLCN KO exit assay are members
of Wnt pathway and ESRRB. Treatment of FLCN KO hESC with a Wnt inhibitor, but not
ESRRB/FLCN double mutant, rescues the cells, allowing the exit from the naïve state. Using
co-immunoprecipitation and mass spectrometry analysis we identify unique FLCN binding
partners. The interactions of FLCN with components of the mTOR pathway (mTORC1 and
mTORC2) reveal a mechanism of FLCN function during exit from naïve pluripotency.
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Unveiling the molecular mechanisms through which plur-ipotency is maintained holds promise for understandingearly animal development, as well as developing regen-
erative medicine and cellular therapies. Pluripotency does not
represent a single deﬁned stage in vivo. Following implantation,
pluripotent naïve epiblast cells transition to a pluripotent stage
primed toward lineage speciﬁcation. Those subtle stages of
pluripotency, with similarities and differences in measurable
characteristics relating to gene expression and cellular phenotype,
provide an experimental system for studying potential key reg-
ulators that constrain or expand the developmental capacity of
ESC1–12. While multiple pluripotent states have been stabilized
from early mouse and human embryos, it is not fully understood
what regulates the transitions between these states.
The molecular mechanisms and signaling pathways involved
in the maintenance and exit from naïve pluripotency have been
extensively studied in mouse, but are still poorly understood in
human13. In mouse, the naive pluripotency program is controlled
by a complex network of transcription factors, including Oct4,
Sox2, Nanog, Klf2/4/5, Tfcp2l1 (Lbp9), Prdm14, Foxd3, Tbx3,
and Esrrb14–18. Interestingly, Esrrb has been shown to regulate
the naïve pluripotent state in mouse19,20, but RNAseq data sug-
gest that existing human ESC lines lack robust expression of
Esrrb1,6,7,11,12,21.
Naïve and primed pluripotent cells have important metabolic
and epigenetic differences1,12,22,2324. We utilize these differences
to design a functional CRISPR-Cas9 screen to identify genes that
promote the exit from human naïve pluripotency. In the screen,
we identify folliculin (FLCN) as one of the genes regulating the
exit. FLCN knockout naïve hESC remain pluripotent since they
retain high levels of the pluripotency marker, OCT4, and early
naïve markers (KLF4, TFCP2L1, DNMT3L). However, we show a
requirement for FLCN to exit the naïve state. During normal exit
from naïve pluripotency, the transcription factor TFE3 is exclu-
ded from the nucleus, while in FLCN KO hESC TFE3 remains
nuclear, maintaining activation of naïve pluripotency targets.
ESRRB KO in FLCN KO hESC does not rescue the phenotypes.
However, we ﬁnd that TFE3 targets involved in Wnt pathway are
up-regulated in FLCN KO and inhibition of Wnt restores the exit
from the naïve state in FLCN KO cells. Mass spectrometry ana-
lysis reveals that FLCN binds to different proteins in the naïve
state and upon exit from the naïve state, allowing us to propose a
new model for the action of FLCN in early pluripotent states.
Results
CRISPR KO screen during exit from human naïve plur-
ipotency. S-adenosyl methionine (SAM) levels, controlled by
nicotinamide N-methyltransferase (NNMT), are critical during
the naïve-to-primed hESC transition, where the epigenetic land-
scape changes through increased H3K27me3 repressive marks1,24.
Using CRISPR-Cas9 technology, we generated NNMT KO naïve
hESC lines1. As expected, SAM levels and H3K27me3 marks are
increased in NNMT KO naïve cells compared to wild type naïve
cells1 (Fig. 1a). Principal component analysis of NNMT KO cells
revealed that their gene expression signature shifts towards the
primed stage, even when grown in naïve-like culture conditions
(2iL-I-F)1 (Supplementary Fig. 1A). However, NNMT KO cells
exhibit only a partial primed gene expression signature. We found
that 913 genes in NNMT KO do not display the expected
methylation pattern for primed cells (Fig. 1b; Supplementary
Data 1A) and 1967 genes down-regulated in primed hESC fail to
decrease expression in NNMT KO cells (Supplementary Fig. 1B,
Supplementary Data 1B). To uncover which factors are regulating
these 1967 genes, we tested their potential enrichment as target
genes of 45 transcription factors based on ENCODE ChIP-seq
data in primed hESCs (Supplementary Fig. 1C). The most
enriched candidate regulators include CTBP2, TAF1, EGR1,
TEAD4 (ref. 5), JUND, SP1, and TFE3, suggesting that these
transcription factors are normally repressed during the exit from
naïve hESC state.
We performed a CRISPR KO screen to test the functionality of
the identiﬁed transcriptional regulators, and to identify additional
genes required for the exit from the human naïve pluripotent
state. To control for hESC cell type variability, we performed the
screen with one naïve cell type and validated the key candidates in
another naïve line, from a different genetic background. Naïve
2iL-I-F hESC were infected with a lentiviral pool containing a
human CRISPR-Cas9 knockout (GeCKO) library targeting 18,080
genes with 64,751 unique sgRNAs25. Cells were allowed to exit
the naive hESC state, and the primed hESC were selectively
eliminated with a mixture of methotrexate and acetaldehyde,
exploiting the differences in the metabolic requirements of these
cell types1 (Fig. 1c). Methotrexate inhibits both methionine
synthase (MS) and S-adenosyltransferase (MAT) activities,
reducing SAM levels26,27. Acetaldehyde also inhibits methionine
synthase28. Primed hESC have higher levels of repressive
histone methylation (H3K27me3) marks, increasing their depen-
dence on SAM levels1,24 and increasing their sensitivity to
methotrexate and acetaldehyde treatment (Fig. 1d). Methotrexate/
acetaldehyde treatment speciﬁcally kills the primed cells and cells
transitioning to the primed state (Fig. 1e). To identify the genes
required for the primed state transition, we analyzed the surviving
cells for enriched sgRNAs (Fig. 1c). We hypothesized that the
survivors had inactivation of genes required for exit from naïve
pluripotency.
The CRISPR screen successfully identiﬁed genes known to
regulate human primed pluripotent stem cells (Supplementary
Data 2 (ref. 29)), and many novel regulators, including GREB1,
FAM60A, UROS, GPI, MED12, TSC2, RELT, CCDC159, NARFL,
and FLCN. These potential regulators of the exit from the naïve
pluripotent state are involved in metabolic switching, signaling,
and chromatin remodeling (Fig. 1f; Supplementary Data 2). As
expected for a negative selection screen relying on apoptotic
activity, the screen also identiﬁed genes required for apoptosis
(Supplementary Data 2). Gene hits of interest were individually
validated (Fig. 1g; Supplementary Data 2). We opted to further
study the role of FLCN, a tumor suppressor mutated in the
Birt–Hogg–Dubé syndrome, in early human pluripotent states30.
Flcn−/− mice are embryonic lethal and exhibit a disorganized
epiblast soon after implantation31. Flcn acts in mouse ESC by
regulating Esrrb function19. However, ESRRB expression is low in
hESC compared to mESC and it is not yet known whether ESRRB
is required in human naïve hESC21, thus the mode of action for
FLCN is not yet understood in human pluripotency.
FLCN is not required to maintain the naïve pluripotent state.
We investigated the role of FLCN in human pluripotency by
generating FLCN KO lines in naïve human ESC. To control for
potential differences in published naïve hESC states, we tested
FLCN function in different naïve growth conditions and in dif-
ferent cellular backgrounds (growth conditions: 5iLA and 2iL-I-F;
cellular background: from the Boston-derived lines we chose
WIBR3 and from Seattle-derived Elm/Elf lines (Supplementary
Fig. 1D) we chose Elf1; refs. 1,4,32).
We generated FLCN KO lines in two cellular backgrounds
(WIBR3 and Elf1) hESC using four guide RNAs targeting FLCN
(Fig. 2a, c; Supplementary Fig. 2A). Guides located in exons 3
and 4 created InDel mutations, introducing STOP codons and
resulting in the absence of FLCN protein (Fig. 2a, c; Supplemen-
tary Fig. 2A). We then generated a FLCN rescue line by
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introducing an inducible FLCN-GFP fusion construct into the
AAVS1 safe harbor site of the naïve FLCN KO line (Fig. 2b).
Overexpression of the FLCN-GFP after doxycycline treatment
was shown by western blot analysis (Fig. 2c; Supplementary Fig.
2B). Immunostaining analysis revealed that FLCN KO naïve
hESC (2iL-I-F and 5iLA) maintain the expression of the
pluripotency factor OCT4 (Fig. 2d). We further performed
RNAseq analysis to compare gene expression changes in the
FLCN KO hESC line vs. the rescue hESC line (FLCN KO vs.
FLCN KO+ FLCN-GFP; Supplementary Fig. 2C, D, Supplemen-
tary Data 3A). In order to assess whether FLCN KO hESC are still
in the naïve state and to identify potential stage-speciﬁc markers
among the differentially expressed genes, we utilized RNAseq
data from non-human primate, cynomolgus monkey, pre-and
post-implantation in vivo blastocysts (Macaca fascicularis33). We
compared the cynomolgus monkey in vivo data to the FLCN KO
with and without the rescue construct (Fig. 2e; Supplementary
Data 3B). Important early naïve pluripotency markers, such as
TFCP2L1 (LBP9), DNMT3L, KLF4, DPPA3, and DPPA2 (ref. 13)
are among the 40 genes that are up-regulated both in FLCN KO
hESC cell culture and in vivo pre-implantation cynomolgus
monkey blastocysts (Fig. 2e, f; Supplementary Fig. 1A, Supple-
mentary Data 3B). t-SNE analysis of the Macaca data conﬁrmed
that DNMT3L and TFCP2L1 are highly expressed in pre-
implantation stages compared to post-implantation stages (Fig.
2f). We validated the up-regulation of DNMT3L and TFCP2L1 by
reverse transcription quantitative PCR (RT-qPCR) in naïve 2iL-I-
F and 5iLA FLCN KO hESC compared to the rescued lines (Fig.
2g, h). Tfcp2l1 is highly expressed in mouse pre-implantation
ICM compared to mouse post-implantation epiblast34,35 and was
proposed as a critical regulator to stabilize both the mouse and
the human ESC naïve state12,36–38. TFCP2L1 controls transpo-
sable elements (TRE)36, and TRE expression has been proposed
as a molecular criterion of early naïve pluripotent stem cells4. We
analyzed the TRE signature and found that FLCN KO naïve (2iL-
I-F) hESC expressed a subset of the early naïve (5iLA) TRE
(Supplementary Fig. 2E; Supplementary Data 3C).
Our data show that when in the naïve state, FLCN KO cells
express early naïve markers also seen in monkey pre-implantation
pluripotent cells (Fig. 2e–h; Supplementary Fig. 2C, E; e.g.
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DNMT3L, TFCP2L1, and TRE), suggesting that FLCN KO
upregulates markers of early primate development. Taken
together, these results show that FLCN is not required to
maintain the naïve pluripotency state.
FLCN is required for hESC to exit from the naïve state. To
further dissect the function of FLCN in hESC, we used the two
naïve hESC conditions (2iL-I-F and 5iLA) and two genetic
backgrounds (Elf1 and WIBR3) to analyze exit from the naïve
hESC stage (Fig. 3a). We ﬁrst tested the differential gene
expression signatures between the FLCN KO mutant and control
lines using RNAseq and bioinformatics platforms after naïve
hESC(2iL-I-F) had been treated 7 days in TeSR medium to
allow exit from naive pluripotency (Supplementary Data 4A).
Principal component analysis revealed that while, after 7 days
of culture in TeSR, naïve hESC moved toward the primed state,
the FLCN KO line was not able to fully transition, remaining
closer to the naive proﬁle (Fig. 3b). We also compared the 7-day
TeSR-treated hESC to the cynomolgus monkey in vivo data33
and found that genes up-regulated in 7D TESR in FLCN KO
hESC are signiﬁcantly enriched for monkey pre-implantation
marker genes (hypergeometric test p-value 1.27 × 10−41) while
genes up-regulated in 7-day TeSR in wild type are signiﬁcantly
enriched for monkey post-implantation marker genes (hyper-
geometric test p-value 5.54 × 10−49) (Fig. 3c; Supplementary
Data 4B, C). We validated these observations by RT-qPCR
and western blot (Fig. 3d–g). When induced to exit the
naïve state by omitting the signaling pathway inhibitors and
activating FGF pathway using TeSR medium, the FLCN KO line
failed to exit (naïve marker DNMT3L still expressed, Fig. 3d;
primed markers IDO1, LDHA, and HIF1α not upregulated,
Fig. 3e, f; Supplementary Fig. 3A; ref. 1). Overexpression of
FLCN rescued these FLCN KO phenotypes (Fig. 3d–f). Collec-
tively, these data indicate that FLCN is required for hESC to
exit the naïve state.
Interestingly, when FLCN KO cells were pushed to exit the
naïve state, they did show some positive markers indicative of a
partially successful transition: NNMT expression was down-
regulated, and JARID2 expression and H3K27me3 marks were
upregulated, reﬂective of primed stage (Fig. 3f–g; see ref. 1). We
tested if overexpression of NNMT (NNMT OE) in the FLCN KO
0
20
40
60
80
100
120
140
160
180
DNMT3L TFCP2L1
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n 
Elf 2iLIF WIBR3 5iLA WIBR3 5iLA FLCN KO
0
1
2
3
4
5
6
7
DNMT3L TFCP2L1
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
sio
n 
WT FLCN KO FLCN KO + FLCN-GFP
a b c
EXON 1 EXON 2
AAVS1 locus
Tet-On FLCN GFP
1 106 264 349 563 579
Longin GEE Domain
1 2 3 4Guides:
Residues:
e f
Naive 2iL-I-F hESC 
DNMT3L
LBP9
g
2i
L-
I-F
 
Expression naive markers in cynomolgus monkey in vivod
FLCN-GFP FLCN
KO
WT
– – – –+ +
STOP
FLCN
Naive 5iLA hESC 
5i
LA
h
FLCN KO
ICM
10
10
–10
–10
–20 –10 0
tSNE1
tS
NE
2
tS
NE
2
10
–20 –10 0
tSNE1
10
10.0
7.5
5.0
2.5
0.0
Log2 (RPM)
8
6
4
2
0
Log2 (RPM)
0
0
10
–10
tS
NE
2
–20 –10 0
tSNE1
10
0
ICM
ICM
Pre-Epi
Pre-Epi
Pre-Epi
Post-Epi
cyESCFF
cyESCoF
PostL–EPI
PostE–EPI
Gast2a
Gast2b
Gast1Pre–EPI
Post–paTE
PreL–TE
PreE–TE
ICM
Hypoblast VE/YE
EXMC
Post-Epi
Post-Epi
Oct4DAPI
Oct4DAPI
**
***
**
***
−10 −5 0 5 10 15
30
25
20
15
10
5
0 −4
−2
0
2
4
6
Log2 (pre-EPI/post-EPI) Log
2 (F
LCN
 KO
/Re
scu
e)
–
Lo
g1
0  
(p 
-
va
lu
e,
 p
re
-E
PI
/p
os
t-E
PI
)
Higher in FLCN KO and pre-EPI
DNMT3L
DPPA3
KLF4
TBX3
DPPA2
LBP9
*** ***
***
***
FLCN KO +
FLCN-GFP
WT +
FLCN-GFP
Naïve 2iL-I-F Naïve 5iLA
Dox
FLCN
Tubulin
FLCN-GFP 100 kDa
55 kDa
Actin
70 kDa
Fig. 2 FLCN KO hESC express naïve pluripotency markers. a Schematic representation of FLCN protein and location of CRISPR guide RNAs used. Sanger
sequencing analysis of Elf1 2iL-I-F FLCN KO hESC reveals introduction of STOP codons in exons 3. b, c Generation of WIBR3 5iLA FLCN KO and Elf1 2iL-I-F
FLCN KO line, and overexpression of FLCN-GFP fusion protein in wild type and FLCN KO background. d The pluripotency marker Oct4 is expressed in
FLCN KO 2iL-I-F and 5iLA hESC. Scale bars represent 50 μm. e Expression pattern of genes up-regulated by FLCN KO compared to genes up-regulated
in monkey pre- vs. post-implantation stage. Red: genes up-regulated in FLCN KO and pre-implantation, known ground state pluripotency markers are
labeled. f tSNE analysis of naïve markers DNMT3L, TFCP2L1, and ESRRB in in vivo blastocysts from non-human primate, cynomolgus monkey (Macaca
fascicularis33). g, h RT-qPCR analysis of naïve markers DNMT3L and TFCP2L1 in naïve 2iL-I-F wild type (WT), FLCN KO, and rescue line (FLCN KO+OE
FLCN-GFP) (g) and in naïve 5iLA WT and FLCN KO (h). S.e.m.; **p < 0.005, ***p < 0.001; two-tailed t-test, n= 3–10 biological replicates
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08020-0
4 NATURE COMMUNICATIONS |          (2019) 10:632 | https://doi.org/10.1038/s41467-018-08020-0 | www.nature.com/naturecommunications
line would alter these phenotypes (Fig. 3h, i). We induced the exit
assay in the FLCN KO; NNMT OE hESC and tested marker
expression. The primed marker, JARID2, was reduced due to
NNMT overexpression in FLCN KO, suggesting that JARID2 is
regulated by NNMT activity (Fig. 3i).
To test FLCN function in different naïve hESC conditions and
genetic backgrounds, we analyzed the capacity of FLCN KO to
exit hESC(5iLA) naïve conditions. When naïve hESC(5iLA) are
induced to exit the naïve stage by eliminating 5iLA and growing
the cells in the presence of bFGF (4–7 days), the control hESC
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colonies downregulated naïve markers (Supplementary Fig. 3B)
and lost the compact and mounded naïve hESC morphology (Fig.
3j). However, when the FLCN KO mutants were grown in this
exit assay, the hESC colonies still exhibited compact and
mounded hESC colony morphology and expressed higher levels
of naïve markers DNMT3L, TFCP2L1, and KLF4 (Fig. 3j, k;
Supplementary Fig. 3B). These data show that regardless of the
naïve hESC growth conditions or genetic background, FLCN is
required for the exit from this hESC pluripotent state.
TFE3 localization is regulated by FLCN in hESC. Analysis of
transcription factor target enrichment in genes downregulated
during hESC exit from the naïve state revealed TFE3 as an
important regulator of the process (Supplementary Fig. 1C).
Furthermore, characterization of transcription factor target
enrichment among the genes upregulated in FLCN KO cells
during the exit assay, also showed TFE3 among the top tran-
scription factors (Fig. 4a). Combined, these results suggest that
TFE3 based regulation of naïve exit was abnormal in FLCN KO
hESC lines. We therefore investigated the potential of FLCN to
regulate TFE3 function in hESC. The transcription factor TFE3
has previously been shown to accumulate in the cytoplasm in
primed cells, both in mouse and human ESC6,19. We analyzed the
localization of TFE3 in naïve (5iLA and 2iL-I-F) and primed
hESC conditions (Fig. 4b–d). TFE3 localized in the nucleus in
naïve 5iLA hESC, both in the nucleus and the cytoplasm in 2iL-I-
F hESC, and mainly in the cytoplasm in primed cell lines and in
cell lines exiting the naïve state (Fig. 4b–d). However, in FLCN
KO lines TFE3 was localized exclusively in the nucleus, regardless
of whether the cells were cultured in the naïve state or pushed to
primed state (Fig. 4c, d). In the FLCN rescue line, TFE3 locali-
zation to the cytoplasm in cells exiting the naïve state was
restored (Fig. 4c). These data show that in hESC, FLCN is
required for regulation of cytoplasmic retention of TFE3.
Based on previously described post-translational regulation of
TFE3 localization, we investigated whether FLCN can affect post-
translational modiﬁcation of TFE339,40. In wild-type hESC, TFE3
molecular weight (MW) increases from 72 to 80 kDa, as cells exit
the naïve pluripotent stage (Fig. 4e, 10D TeSR). This increase in
TFE3 protein size is a result from phosphorylation of TFE3 and
has been proposed to be responsible for the cytoplasmic retention
of TFE339,40. The phosphorylated TFE3 is missing in FLCN KO,
suggesting that FLCN is required for this modiﬁcation. However,
we observed a higher molecular weight TFE3 protein (around
89–100 kDa) in FLCN KO hESC, consistent with previous reports
in MEF and mouse kidney cells40,41. TFE389kDa was not removed
upon phosphatase treatment40 and our RNAseq analysis revealed
that only one TFE3 isoform corresponding to the 72 kDa band is
expressed in naïve hESC and hESC exiting naïve state, suggesting
that TFE3 undergoes another post-translational modiﬁcation in
FLCN KO hESC.
WNT inhibition rescues the FLCN KO phenotype. We
demonstrated that when FLCN function is lost, naïve cells cannot
develop to the primed state since the exit from naïve pluripotency
is blocked by restriction of TFE3 localization to the nucleus
(Figs. 3 and 4c, d). TFE3 has been shown to regulate the tran-
scription of the core pluripotency factor Esrrb in mouse ESC19.
However, even though ESRRB is an essential factor in mouse
ground state19,20,37,42, RNAseq data suggest that it is expressed at
a very low level in stabilized hESC lines (Supplementary Fig. 4A)
and in the pre-implantation epiblast of cynomolgus monkey (see
ref. 33, Supplementary Fig. 4B). Interestingly, ESRRB expression is
observed in early ICM of cynomolgus monkey in vivo (Supple-
mentary Fig. 4B)33. We analyzed ESRRB expression by RT-qPCR
and western blot and were able to detect ESRRB transcript and
protein in hESC (Fig. 4g; Supplementary Fig. 4C, D). Of the
differentially expressed genes in naïve 2iL-I-F FLCN KO hESC vs.
naïve 2iL-I-F wild-type hESC, 672 out of 1787 upregulated genes
are TFE3 targets (overlap hypergeometric test p-value 7.01 ×
10–126; Fig. 4f, Supplementary Data 3A), including ESRRB,
TFCP2L1, and members of the Wnt pathway (Fig. 4f; see ref. 20).
FLCN KO up-regulates ESRRB expression in the naïve state but
not upon exit from human naïve pluripotency (Fig.4f, i; Supple-
mentary Data 3A and 4A; Supplementary Fig. 4C, D), suggesting
that ESRRB is not responsible for the FLCN KO phenotype.
Furthermore, FLCN;ESRRB double KO or FLCN KO; ESRRB
mutant are not able to rescue the FLCN KO mutant phenotypes
in transition assays (Fig. 4g, h; Supplementary Fig. 4E–H). ESRRB
reduction does not upregulate the primed markers HIF1α and
LDHA or downregulate the naïve TFCP2L1, DNMT3L, and
KLF4. These data suggest that TFE3-dependent overexpression of
ESRRB cannot be causal for the lack of FLCN KO to exit the 5iLA
and 2iL-I-F states. Knock-down (KD) of TFCP2L1 with a lenti-
virus expressing shRNAs targeting TFCP2L1 slightly decreased
KLF4 expression but did not affect DNMT3L expression in FLCN
KO exiting the naive 5iLA state, suggesting that TFCP2L1 plays a
minor role on FLCN phenotype (Supplementary Fig. 4I–L). KLF4
is also upregulated in FLCN KO and KLF4 KD with shRNA
partially decreases naïve hESC markers DNMT3L and TFCP2L1.
However, since KLF4 is not a predicted TFE3 target, KLF4 cannot
explain the mechanism of FLCN function during the exit from
naïve pluripotency (Supplementary Fig. 4I–L).
To identify the genes in FLCN KO cells that are causal for the
defective exit from the naïve state we analyzed differentially
expressed genes in a transition assay; in TeSR 7D 673 out of 1952
upregulated genes in FLCN KO hESC vs. wild-type hESC were
TFE3 targets (overlap hypergeometric test p-value 2 × 10–69; Fig.
4i; Supplementary Data 4D). As seen in naïve state (Fig. 4f)
among these TFE3 target genes were several members of the
WNT pathway, including WNT ligands WNT3A, WNT5B,
WNT6, and WNT11. FLCN KO also resulted in up-regulation
of WNT targets during the exit form naïve pluripotency (Fig.
4i–l). We tested if WNT pathway up-regulation in FLCN KO was
causal for the inability to exit from naïve pluripotency by using an
inhibitor of WNT processing and secretion, IWP2 and analyzing
genome wide gene expression changes by RNA seq. Principal
component analysis of the gene expression changes revealed that
Wnt inhibition in FLCN KO cells rescued the defect in exit from
human naïve pluripotency (Fig. 4m), allowing up-regulation of
primed markers and down-regulation of naïve markers, as seen in
wild-type hESC exiting the naïve state (Supplementary Fig.
5A–C). The data suggest that TFE3-dependent WNT expression
blocks the exit from the naïve state (5iLA and 2iL-I-F) in FLCN
KO hESC.
FLCN acts through mTORC1 and mTORC2. To reveal the
mechanism of FLCN function in pluripotency, we investigated
why FLCN expression is critical during exit from the naïve
pluripotent stage. FLCN expression levels are similar in naïve
and primed hESC lines in vitro or in cynomolgus monkey pre-
and post-implantation stages in vivo (Supplementary Fig. 5D,
E). We hypothesized that FLCN could form different com-
plexes at different pluripotency states. In order to uncover the
proteins interacting with FLCN, we performed immunopreci-
pitation (IP) of FLCN-GFP in FLCN KO cells, followed by
mass spectrometry analysis in naïve cells and cells exiting the
naïve state (3D TeSR). We found that FLCN is associated with
its known interactors FNIP1 and FNIP2, as well as desmosome
proteins, HDAC6 and Caspase 14, among others (Fig. 5a,
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Supplementary Data 5). Interestingly the mTORC2 component
MAPKAP1(SIN1) was found in a complex with FLCN only in
naïve hESC while TIPRL, ARAP1, RAP2B, CD59, and PLCH1
were found in a complex with FLCN only in cells exiting the
naïve state (Fig. 5a; Supplementary Data 5). We validated the
speciﬁc binding of SIN1 to FLCN in naïve hESC by IP of
FLCN-GFP followed by western blot analysis (Supplementary
Fig. 6A).
Since FLCN and several of its new binding interactors have
been previously associated with mTOR pathways30,31, we assessed
the phosphorylation status of mTor as well as mTORC1 and
mTORC2 targets (S6 and AKT(S473), respectively) in hESC
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grown in various conditions (5iLA, 2iL-I-F, FGF, and TeSR).
FLCN KO resulted in increased phosphorylation of mTOR, S6,
and AKT(S473) in naïve cells (5iLA and 2iL-I-F) but not in cells
exiting the naïve state (FGF and TeSR) (Fig. 5b; Supplementary
Fig. 6B). Interestingly, FLCN does not seem to affect the
phosphorylation of AKT on T308 (Supplementary Fig. 6C).
These data suggest that FLCN inhibits mTORC2 and mTORC1
in the naïve state.
To analyze the mTORC2 function in naïve-to-primed transition
we generated mutant alleles for SIN1 (MAPKAP1) in hESC (Fig.
5d). While no obvious defects were observed in naïve SIN1 mutant
hESC (Fig. 5f; Supplementary Fig. 6D), during primed transition
mTORC2 target, P-AKT(S473) was downregulated (Fig. 5e).
Interestingly, mTORC1 target P-S6 was downregulated in SIN1
mutants, suggesting that a branch of mTORC1 is downstream of
mTORC2 in primed hESC (Fig. 5f). mTORC2-independent roles
of SIN1 have been described43,44. We therefore generated KD of
another member of mTORC2, RICTOR in hESC and found that a
decrease of RICTOR expression also downregulated P-AKT(S473)
and P-S6 during primed transition, mimicking SIN1 mutant
phenotype in cells exiting the naïve state (Fig. 5g).
We then analyzed whether mTORC1 and/or mTORC2 affect
the localization of TFE3. We treated hESC exiting the naïve state
with a mTORC1/2 inhibitor, INK-128 and mTORC1-speciﬁc
inhibitor Rapamycin (Fig. 5c, h). While TFE3 exited the nucleus
in control hESC in the primed stage, TFE3 did not exit the
nucleus after cells were treated with INK-128 or Rapamycin (Fig.
5h), suggesting that TFE3 localization in hESC is controlled by
mTOR activity. To analyze mTORC2 function in TFE3 localiza-
tion we tested TFE3 localization in the SIN1 and RICTOR
mutants. We show that mTORC2 is dispensable for TFE3 release
from the nucleus since TFE3 exits the nucleus in SIN1 and
RICTOR mutants during hESC naïve-to-primed transition (Fig.
5h). The speciﬁc inhibition of mTORC1 by Rapamycin,
evidenced by decrease of P-S6 and P-4EBP1, but not P-AKT
(S473), represses TFE3 exit from nucleus in the naïve-to-primed
transition assay (Fig. 5c, h; Supplementary Fig. 6F–H). These data
suggest that mTORC1, but not mTORC2, is required for TFE3
exit from the nucleus in hESC primed stage (Fig. 5h).
mTOR requirement in primed hESC was further reciprocated
with a small-molecule screen. We tested compound sensitivity
proﬁles of naïve and primed hESC in a high throughput screen of
160 approved and investigational oncology drugs (Supplementary
Fig. 6E). Compounds were added at concentrations ranging
from 5 pM to 100 μM using the CyBio CyBi-Well Vario and
incubated at 37 ºC, 5% CO2 for 72 h. Viability was assessed using
quantitation of luminescence derived from intracellular ATP. The
most signiﬁcant new set of small molecules that reduced primed
but not naïve hESC viability was mTOR/PI3K/AKT inhibitors
(AZD-8055, BEZ-235, BGT-226, BKM-120, Everolimus, GDC-
0941, OSI-027, PF-04691502, PKI-587, Pp-242, Rapamycin,
Temsirolimus), suggesting that both mTORC1 and mTORC2
are critical for primed hESC stage.
Similar results have been obtained recently using haploid
cells45.
Discussion
Our CRISPR-Cas9 KO screen led to identiﬁcation of new reg-
ulators of the exit from naïve pluripotency in humans, including
FLCN. We showed that FLCN controls the localization of
the transcription factor TFE3 through the mTOR pathway.
Localization of TFE3 in the nucleus results in the transcriptional
activation of the WNT pathway, thereby retaining the hESC in
the naïve stage. Inhibiting the WNT pathway rescues the
capacity of a FLCN KO hESC line to exit naïve pluripotency,
suggesting that a key TFE3 target, regulated by FLCN in hESC
is the WNT pathway.
The tumor suppressor, cytoplasmic guanine exchange factor
FLCN, is associated with Birt–Hogg Dubé syndrome, which is
characterized by multiple benign hair follicle tumors, renal and
pulmonary cysts, and increased susceptibility to kidney cancer30.
Interestingly, Gene Ontology analysis reveals that genes involved
in regulation of kidney development are enriched in FLCN KO vs.
FLCN KO+ FLCN-GFP rescue (Supplementary Fig. 2E). FLCN
has been shown to regulate various signaling pathways and cel-
lular metabolism through mTOR, AMPK, HIF1α, ciliogenesis,
autophagy, and lysosomal biogenesis30,46. It is an essential protein
required for Drosophila germline stem cell maintenance and
hematopoietic stem cell maintenance31,47,48. However, Flcn is
not required for the maintenance of mouse ESC19,31 or naïve
hESC (this study), suggesting that Flcn function is context
dependent. Mouse Flcn−/− embryos die soon after implantation,
and Flcn KD mouse ESC loose the capacity to differentiate19,31.
This phenotype is at least partly due to the fact that FLCN
controls the nuclear localization of a key stem cell transcription
factor, TFE3 (refs. 19,40,47).
Recent ﬁndings have revealed that FLCN acts at the lysosomal
membrane, interacting with Rag GTPase49,50. This interaction
regulates amino acid-dependent activation of mTOR. Further-
more, amino acid induced action of FLCN as a guanine nucleo-
tide exchange factor for RagA/B-complex51 and a GTPase-
activating protein for RagC/D49 activates Rag and mTOR, which
could phosphorylate MiT-TFE transcription factors, allowing
them to move out of the nucleus39. Although TFE3 is localized in
the nucleus in naïve hESC but in the cytoplasm in primed hESC
or hESC exiting the naïve state, this localization difference cannot
be explained by the level of expression of FLCN, since FLCN is
expressed at the same level in various pluripotent states. FLCN
has been shown to interact with FLCN Interacting Proteins 1 and
2 (FNIP1/2)31,47,52. We showed by co-immunoprecipitation of
FLCN-GFP followed by mass spectrometry analysis that FLCN
also binds to FNIP1/2 in hESC. In addition, FLCN binds to TOR
Signaling Pathway Regulator (TIPRL) upon exiting from the
naïve state but not in the naïve state, i.e., mTOR signaling
pathway mechanics change as cells progress from naïve to
Fig. 5 FLCN differentially regulates mTOR pathway in various pluripotency states. a Proteins associated with FLCN were co-immunoprecipitated and
identiﬁed using mass spectrometry. Protein abundance (label free quantiﬁcation (LFQ) intensity) differences were quantiﬁed between plus and minus dox-
treated cell lines. Black line represents the 5% false discovery rate calculated in Perseus 1.5.6. N= 3–4 technical measurements. bWestern blot analysis of
p-mTor, mTOR, p-AKT(Ser 473), AKT, p-S6, and S6 in WT or FLCN KO naïve hESC (5iLA, 2iL-I-F) and hESC growing in FGF (7D) or TeSR (7D). c Effect of
Rapamycin and INK-128 on naïve hESC and hESC exiting the naïve pluripotent state. Naïve 5iLA and 7D TeSR hESC were treated with either DMSO
(control), INK-128 (100 nM), or Rapamycin (100 nM) for 24 h (at day 6 for 7D TeSR cells). d Western blot analysis of SIN1 expression in naïve (2iL-I-F)
hESC WT and SIN1 mutant lines. e, f SIN1 mutant hESC exhibit a reduction of p(S473)AKT (e) and pS6 (f) in cells exiting the naïve state (TeSR 7D).
g RICTOR mutant hESC exhibit a reduction of p(S473)AKT and pS6 in cells exiting the naïve state (TeSR 7D). h TFE3 is observed in the cytoplasm of hESC
exiting the naïve state (Elf1 2iL-I-F→ 4D TeSR, WT, SIN1 mutant clone #18, RICTOR KD mutant) and in the nucleus when treated for 24 h with mTORC1
inhibitor Rapamycin (100 nM) or mTORC1/2 inhibitor INK-128 (100 nM), using confocal microscopy. Scale bars represent 50 μm. i Hypothetical model of
FLCN-regulation of mTORC1, mTORC2, and TFE3 localization in hESC
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primed. TIPRL has been shown to enhance amino acid-
dependent mTORC1 signaling by inhibiting the phosphatase
activity of PP2Ac53. We propose that the formation of a FLCN/
FNIP1/TIPRL complex in cells exiting the naïve state could
activate mTOR at the lysosome (through Rags) and induce
phosphorylation of TFE3 resulting in its retention in cytoplasm
(Fig. 5i).
In cancer cells FLCN mutants exhibit activation of both
mTORC1 and mTORC2 and treatment of a mouse model of Flcn
mutant-induced renal carcinoma with mTor inhibitor reduces
tumor size31. However, the mechanism of how FLCN controls
both mTORC1 and mTORC2 function is unknown. It has been
proposed that naïve and primed hESC are differentially depen-
dent on mTORC2 (ref. 54). Here we show that FLCN can bind to
SIN1, an essential component of mTORC2 (ref. 55) only in the
naïve state. Using SIN1 and RICTOR-speciﬁc mutant we show
that while mTORC1 is important for TFE3 localization, mTORC2
is dispensable for the process. Reduction of either SIN1 or RIC-
TOR expression decreased the levels of P-S6, in addition to P-
AKT(S473), suggesting that mTORC2 can partially regulate
mTORC1 in hESC, as seen previously in mESC56. Future
experiments will reveal the function of this branch of mTORC1
regulation. We propose that FLCN/SIN1 interaction may nega-
tively regulate mTORC2 activity, and consequently cytoplasmic
mTORC1 activity (Fig. 5i). However, we cannot rule out that the
binding of FLCN to SIN1 in naïve hESC could also regulate
mTORC2-independent functions of SIN1 (refs. 43,44). It is pos-
sible that FLCN may not directly interact with mTORC2 but
rather may sequester SIN1 from this complex. The role of
mTORC2 and cytoplasmic mTORC1 in the exit from naïve
pluripotency remains to be identiﬁed. Interestingly we also found
that during the exit of naïve pluripotency FLCN binds to ARAP1,
RAP2B, CD59, and PLCH1, four proteins involved in the EGFR
signaling pathway, corroborating the recent ﬁndings that FLCN
negatively regulates EGFR signaling57. The role of FLCN on
EGFR pathway in hESC will be interesting to examine further in
future studies, in particular its role upstream of AKT and mTOR
pathway.
In human ESC, we observed that in the absence of FLCN, TFE3
is exclusively localized to the nucleus, resulting in the activation
of its target genes. TFE3 has been shown to regulate the tran-
scription of the core pluripotency factor Esrrb in mouse ESC19.
However, ESRRB expression is low in hESC lines13,58, suggesting
that TFE3 targets are different in human and mouse. KO of
ESRRB in naïve FLCN KO hESC does not signiﬁcantly decrease
the expression of naïve markers during the naïve to primed
transition. Among the genes up-regulated in FLCN KO hESC
were several TFE3-targets WNT ligands, as well as WNT pathway
targets, indicating WNT pathway activation. WNT plays an
essential role in maintaining the naïve pluripotent state in mouse
and human ESC1,20,59,60. Since the expression of Wnt has been
shown to block the transition from naïve to primed ESC60, we
hypothesized that activation of the WNT pathway by TFE3 in
FLCN KO hESC prevents the cells from exiting the naïve state.
We conﬁrmed that hypothesis by showing that WNT inhibitor
was able to rescue the FLCN KO phenotype. These studies may
have bearing for novel treatments of human cancer caused by
Folliculin mutations.
Methods
hESC culture. Naïve hESC [Elf-1 (NIH_hESC Registry #0156), Elm-2 (NIH_hESC
Registry #0396), Elf-3 (NIH_hESC Registry #0397), Elf-4 (NIH_hESC Registry
#0398), and WIBR3 (NIH registry#0079) toggled in 5iLA] were cultured as pre-
viously described1,3,4,32. Brieﬂy, cells were grown on a feeder layer of irradiated
primary mouse embryonic ﬁbroblasts (MEF) in naïve hESC media (2iL-I-F or
5iLA). 2iL-I-F media consisted of DMEM/F-12 media supplemented with 20%
knockout serum replacer (KSR), 0.1 mM nonessential amino acids (NEAA), 1 mM
sodium pyruvate, penicillin/streptomycin (all from Invitrogen, Carlsbad, CA),
0.1 mM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO), 1 µM GSK3 inhibitor
(CHIR99021, Selleckchem), 1 µM of MEK inhibitor (PD0325901, Selleckchem),
10 ng ml−1 human LIF (Chemicon), 5 ng ml−1 IGF1 (Peprotech) and 10 ng ml−1
bFGF. 5iLA media consisted of 50:50 mixture of DMEM/F-12 (Invitrogen; 11320)
and Neurobasal (Invitrogen; 21103) media, supplemented with 1% N2 supplement
(Invitrogen; 17502048), 2% B27 supplement (Invitrogen; 17504044), 1 mM gluta-
mine (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM β-
mercaptoethanol (Sigma), penicillin–streptomycin (Invitrogen), 50 mgml−1
bovine serum albumin (BSA) (Sigma), BRAF inhibitor (0.5 µM), SRC inhibitor
(1 µM), MEK inhibitor (1 µM), GSK3 inhibitor (IM-12, 1 µM), ROCK inhibitor
(10 µM), recombinant human LIF (20 ng.ml−1), and Activin A (10 ng ml−1). Cells
were passaged using 0.05% Trypsin-EDTA (Life Technologies). Cells were trans-
ferred to matrigel-coated plates prior molecular analysis. Exit from the naïve state
was achieved by culturing the cells in either mTeSR1 media (StemCell Technolo-
gies) or primed FGF hESC media (DMEM/F-12 media supplemented with 20%
KSR, 0.1 mM NEAA, 1 mM sodium pyruvate, penicillin/streptomycin, 0.1 mM
β-mercaptoethanol, and 10 ng ml−1 bFGF) on matrigel-coated plates. All cells were
cultured at 5% O2 and 5% CO2 between passage p20 and p40, as indicated.
Whole-genome CRISPR screen during exit from naïve state. Ten to 20 million
naïve hESC Elf1 2iL-I-F (passage p21–p26) were transduced with human pooled
lentiCRISPR library (genome-scale CRISPR-Cas9 knockout (GeCKO) library25) via
spinfection and plated onto irradiated Drug Resistance 4 (DR4) MEF. Four days
later, puromycin was added (0.5 µg ml−1) for 2 days. Cells were passaged at day 7
and day 10. On day 10, cells were switched to TeSR media to initiate the exit from
the naïve state. After 4 days in mTeSR1, cells were treated with Methotrexate
(1 µM; Torcis) and Acetaldehyde (1 mM; Sigma) (M/A). In all, 3–4 × 5 millions
cells were harvested at Day 14 time point (before M/A selection) and at Day 17
(3 days after beginning of M/A selection). Genomic DNA was extracted and
sgRNA sequences were PCR ampliﬁed and sequenced. Bowtie61 was used to align
the sequenced reads to the sgRNA library and the R/Bioconductor package
edgeR62,63 with voom normalization64 was used to assess changes across various
groups. Guides having a fold change greater than 1 and an adjusted false discovery
rate (FDR) >0.05 were considered statistically signiﬁcant. Raw and mapped data
ﬁles are available at the Gene Expression Omnibus database (GSE).
Generation of CRISPR mutant lines. Naïve hESC (Elf1 2iL-I-F or WIBR3 5iLA)
were spin-infected with lentiCRISPR-v2 lentiviral pools of four sgRNA per gene for
FLCN and ESRRB in the presence of 4 µg ml−1 polybrene (Supplementary
Data 6A) and plated onto irradiated DR4 MEF. Two days later, cells were selected
with puromycin (0.5 µg ml−1, for 2–3 days). Alternatively, SIN1 and RICTOR
mutants were generated in Elf1-iCas9 (ref. 1). Guides were ordered through Syn-
thego (RICTOR) or as T7-gRNA primers (SIN1). A dsDNA fragment was syn-
thesized from these primers by self-annealing PCR to a complementary scaffold
primer. The dsDNA fragment was followed by Q5 High-Fidelity-based PCR (New
England Biolabs). This 120 bp strand served as a template for IVT (MAXIscript T7
kit; Applied Biosystems). The RNA was then puriﬁed using Pellet Paint® Co-
Precipitant (Novagen). Elf1-iCas9 cells were treated with doxycycline (2 μg ml−1)
for 2–3 days before and during transfection. Cells were transfected with 40 nM of
gRNA using Lipofectamine RNAiMAX (Life Technologies). A second transfection
was performed after 24 h. Two days after the last gRNA transfection, Elf1-iCas9
cells were dissociated into single cells and replated onto MEF-coated plates or
collected for DNA analysis (pool). In the next passage, single colonies from MEF-
coated plates were randomly selected and ampliﬁed. The molecular characteriza-
tion of the mutant lines and their phenotype were analyzed between passage 33 and
40 using controls with matching passage number.
Genomic DNA was extracted using DNAzol reagent (Invitrogen) according to
the manufacturer’s instructions and quantiﬁed using Nanodrop ND-1000.
Genomic regions ﬂanking the CRISPR target sites were PCR ampliﬁed with the
designed primers (Supplementary Data 6C) and sent for Sanger sequencing.
Alternatively, PCR were puriﬁed with the PureLink Quick PCR Puriﬁcation Kit
(Invitrogen), inserted into a carrier vector by Gibson Assembly, and 96 clones
Sanger sequenced.
Secondary CRISPR screen. Newly generated naïve hESC (Elf1 2iL-I-F) CRISPR
KO were pushed to exit the naïve pluripotent state by switching their media
with mTeSR1. Four days later, cells were treated with methotrexate (1 µM) and
acetaldehyde (1 mM) for three additional days. Number of surviving cells was then
assessed using NucleoCounter NC-200 (ChemoMetec).
Generation of FLCN and NNMT overexpression constructs. NNMT gene was
ampliﬁed from the pCLNCX-NNMT OE construct65 using PCR with Q5 High-
Fidelity DNA Polymerase (New England Biolabs). PCR product was Gibson
assembled into mammalian vector AAVS1-TRE3G-EGFP66. Full-length FLCN was
ampliﬁed out of a cDNA library and inserted into the MluI site of AAVS1-TRE3G-
EGFP by Gibson Assembly. 1 × 106 cells of naïve FLCN KO hESC (Elf1 2iL-I-F)
were transfected with 0.5 µg AAVS1-TALEN-R plasmid (Addgene #59026), 0.5 µg
AAVS1-TALEN-L (Addgene #59025), and 4 µg of either AAVS1-TRE3G-NNMT-
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08020-0
10 NATURE COMMUNICATIONS |          (2019) 10:632 | https://doi.org/10.1038/s41467-018-08020-0 | www.nature.com/naturecommunications
EGFP or AAVS1-TRE3G-FLCN-EGFP using Amaxa Lonza Human stem cell Kit
#2. The cells were then plated with 5 µM ROCK inhibitor onto irradiated DR4
MEF. Two days following the nucleofection, the cells were selected for Puromycin
0.5 µg ml−1 for 2 days.
Generation of KLF4 and TFCP2L1 knock-down lines using shRNA. shRNA
against TFCP2L1 or KLF4 were inserted in the lentiviral backbone pLL3.7-EF1a-
GFP (shRNA-GFP). WIBR3 5iLA FLCN KO cells were infected with pooled
TFCP2L1 or KLF4 shRNA-GFP virus in the presence of polybrene (4 µg ml−1
polybrene). The GFP expression was used to measure transfection efﬁciency. The
knock-down efﬁciency of the shRNA was assessed by RT-qPCR and western blot
analysis. Sequences of shRNA used are presented in Supplementary Data 6B.
ChIP-seq experiment. Naïve 2iL-I-F hESCs Elf1 NNMT KO (mutant 6.2.4; ref. 1)
were crosslinked and chromatin processed as previously described1 with minor
modiﬁcations. Brieﬂy, cells were harvested with accutase and crosslinked in
suspension with 1% formaldehyde solution for 10 min at room temperature.
Reaction was quenched with glycine and crosslinked cells were rinsed with ice-cold
phosphate-buffered saline (PBS). Nuclei were isolated and chromatin sonicated
using a Covaris E210 to approximately 200–500 bp size range. Magnetic Dynabeads
were incubated overnight rotating at 4 °C with antibody against H3K27me3 (Active
Motif, cat # 39155). Sonicated chromatin from approximately 200 thousand to 3
million cells was added to the bead-bound-antibodies and allowed to incubate at
4 °C rotating overnight. Beads were washed to remove unbound chromatin. Bound
chromatin was eluted from beads and reverse crosslinked overnight. Puriﬁed DNA
was prepared for next-generation sequencing via end repair, A-tailing, ligation of
custom Y-adapters, and PCR ampliﬁcation to generate ﬁnal DNA library following
gel size selection.
WNT and mTORC1/2 chemical inhibition. Wnt secretion was inhibited in hESC
Elf1 and WIBR3 during the exit of the naïve state (7 days in either mTeSR1 or FGF,
respectively) by treatment with IWP2 (7 days, 2 μM; Tocris). Dimethyl sulfoxide
(DMSO) treatment was used as a vehicle control. mTORC1/2 activity was inhibited
in hESC Elf1 during the exit of naïve state (4 days in mTeSR1) by treatment with
INK-128 (100 nM; Medchem) or Rapamycin (100 nM) for 24 h (added 6 days after
mTeSR1).
Immunoﬂuorescence staining. Cells were ﬁxed in 4% paraformaldehyde in PBS
for 10 min, permeabilized for 10 min in 0.1% Triton X-100, and blocked for 1 h in
2% BSA. The cells were then incubated in primary antibody overnight, washed with
PBS (3 × 5 min), incubated with the secondary antibody in 2% BSA for 1 h, washed
(3 × 10 min) and stained with 1 μg ml−1 DAPI for 10 min. Mounting media was
composed of 2% of n-propyl gallate in 90% Glycerol and 10% PBS. Analysis was
done on a Leica TCS-SPE Confocal microscope using a ×40 objective and Leica
Software. The antibodies used for immunostaining were anti-TFE3 (Sigma Prestige
HPA023881, 1:400), anti-Oct4 (Santa Cruz sc-5279, 1:100), and Alexa 488- or
Alexa 647-conjugated secondary antibodies (Molecular Probes).
Western blots analysis. Cells were lysed directly on the plate with a lysis buffer
containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 15% glycerol, 1% Triton x-100,
1 M ß-glycerolphosphate, 0.5 M NaF, 0.1 M sodium pyrophosphate, orthovanadate,
PMSF, and 2% sodium dodecyl sulfate (SDS). Twenty-ﬁve units of Benzonase®
Nuclease (EMD Chemicals, Gibbstown, NJ) was added to the lysis buffer right
before use. Proteins were quantiﬁed by Bradford assay (Bio-rad), using BSA as
Standard using the EnWallac Vision. The protein samples were combined with the
4× Laemmli sample buffer, heated (95 °C, 5 min), and run on SDS-PAGE (protean
TGX pre-casted 7.5% gel or 4–20% gradient gel; Bio-rad) and transferred to the
nitro-cellulose membrane (Bio-Rad) by semi-dry transfer (Bio-Rad). Membranes
were blocked for 1 h with 5% milk or 2% BSA (for antibodies detecting phos-
phorylated proteins), and incubated in the primary antibodies overnight at 4 °C.
The antibodies used for western blot were β-tubulin III (Promega G7121, 1:1000),
β-actin (Cell Signaling 4970, 1:10000), Oct4 (Santa Cruz sc-5279, 1:1000),
H3K27me3 (Active Motive 39155, 1:1000), FLCN (Cell Signaling D14G9, 1:2000),
NNMT (Abcam 58743, 1:500), TFE3 (Sigma Prestige HPA023881, 1:1000), JARID2
(Cell Signaling D6M9X, 1:1000), LDHA (Cell Signaling 2002, 1:1000), SIN1 (EMD
Millipore 05-1044, 1:000), pAkt(S473) (Cell Signaling 9271, 1:1000), pAkt(T308)
(Cell Signaling 9275, 1:1000), Akt (Cell Signaling 9272, 1:1000), pS6 (Cell Signaling
2215, 1:10,000), S6 (Cell Signaling 2117, 1:2000), p4EBP1 (Cell Signaling 236B4,
1:1000), ESRRB (ProteinTech, 1:1000), pmTOR (Cell Signaling 2971, 1:1000),
mTOR (Cell Signaling 2972, 1:1000), RICTOR (Invitrogen MA5-15681, 1:1000),
TFCP2L1 (Novus Biologicals NBP1-85441, 1:1000), and KLF4 (Abcam ab129473,
1:1000). The membranes were then incubated with secondary antibodies (1:10,000,
goat anti-rabbit or goat anti-mouse IgG HRP conjugate(Bio-Rad) for 1 h and
the detection was performed using the immobilon-luminol reagent assay (EMD
Millipore). Uncropped scans of the most important blots are presented in
Supplementary Data 7.
Co-immunoprecipitation. Elf1 FLCN KO+FLCN-GFP hESC grown in either
naïve media (2iL-I-F) or mTeSR1 media (3–4 days) plus or minus doxycycline
(1 μg ml−1) were incubated directly on the plate with 200 µl lysis buffer (10 mM
Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1.5 mM MgCl2, 1 mM DTT,
25 mM NaF, 5% glycerol, 0.5% NP-40, (1 tablet/10 ml) PMSF added freshly). The
lysate was transferred to a microtube and incubated on ice for 30 min with
extensive vortexing every 10 min. Cell lysate was centrifuged at 15,600 × g for
15 min at 4 °C. One hundred and ﬁfty microliters supernatant were incubated for
1 h at 4 °C with 20 µl of GFP-Trap-A beads (gta-20; Chromotek) used as per the
manufacturer’s protocol. The bound protein was separated by centrifugation
(200 × g for 2 min at 4 °C) where the unbound-ﬂowthrought was removed and the
beads were washed extensively four times using lysis buffer and centrifugation at
200 ×g for 2 min at 4 °C. Finally, the beads were resuspended in 40 µl of sample
buffer 2× and 20 µl were loaded on gel.
Proteomics. Immunoprecipitated proteins were suspended in 1M urea, 50 mM
ammonium bicarbonate, pH 7.8, and heated to 50 °C for 20 min. Proteins were
reduced with 2 mM DTT, alkylated with 15 mM iodoacetamide, and digested
overnight with trypsin. The resulting peptides were desalted on Waters Sep-Pak
C18 cartridges. Peptides were measured by nano-LC-MS/MS on a Fusion Orbitrap
(Thermo Fisher Scientiﬁc). Peptides were separated online by reverse phase
chromatography using a heated 50 °C 30 cm C18 columns (75 mm ID packed with
Magic C18 AQ 3 μM/100Α beads) in a 280 min gradient (1–45% acetonitrile with
0.1% formic acid) separated at 250 nl min−1. The fusion was operated in data-
dependent mode with the following settings: 30,000 resolution, 350–1500m/z full
scan, top speed 2 s, and an 1.8m/z isolation window. Identiﬁcation and label free
quantiﬁcation of peptides were done with MaxQuant 1.5.7.4 using a 1% FDR
against the human Swiss-Prot/TrEMB database downloaded from Uniprot on
2 June 2016. The databases contained forward and reverse human sequences as
well as common contaminants. Peptides were searched using a match between
run window of 2 min, 5 ppm mass error, a maximum of two missed cleavages,
modiﬁcation of cysteine residues (alkylation +57.0215 Da), methionine (oxidation
+15.9949 Da), asparagine and glutamine (deamidation +0.9840), and acetylation
of protein n-termini (+42.0106 Da). Proteins that were signiﬁcantly regulated
between conditions were identiﬁed using a permutation-based t-test (S1, FDR 5%)
in Perseus 1.5.6. We analyzed two biological experiments with 3–4 technical
replicates per condition.
RNA extraction and RT-qPCR analysis. RNA was extracted using Trizol (Life
Technologies) according to the manufacturer’s instructions. RNA samples were
treated with Turbo DNase (ThermoFischer) and quantiﬁed using Nanodrop
ND-1000 (Thermo Scientiﬁc). Reverse transcription was performed using Random
Hexamers (Invitrogen) and Omniscript reverse transcription kit (Qiagen). Ten
nanograms of cDNA were used to perform qRT-PCR using SYBR Green (Applied
Biosystems) or TaqMan (Applied Biosystems). Primers used are listed in Supple-
mentary Data 6D. Real-time RT-PCR analysis was performed on 7300 real-time
PCR system (Applied Biosystems). ß-Actin was used as an endogenous control.
RNA-seq and data analysis. Total RNA for samples in this study were extracted
with the Direct-zol RNA kit (Zymo Research) and libraries for Illumina sequencing
were generated with the KAPA Stranded mRNA-Seq Kit (KAPA Biosystems).
Sequencing was run on an Illumina HiSeq 2500 in the Fred Hutchinson Cancer
Research Center Shared Resources Genomics facility. RNA-seq samples from
this study and previously published studies1,4,7,12,67,68 were aligned to hg19
using Tophat69 (version 2.0.13). Gene-level read counts were quantiﬁed using
featureCounts (24227677)70 using Ensembl GRCh37 gene annotations. Raw
sequencing data and read count per gene data can be accessed at the NCBI Gene
Expression Omnibus. Batch effects were corrected using Combat71. Processed
single-cell RNA-seq data from Nakamura et al.33 were used. Only genes expressed
above 10 Reads Per Million in three or more samples were kept. t-SNE72 was
performed with the Rtsne package, using genes with the top 20% variance across
samples. Cluster labels from Nakamura et al.33 were used.
Small-molecule screen for naïve and primed hESC. Compound sensitivity
proﬁles of ELF1 naïve and ELF1 primed cells were compared in a high throughput
screen of 160 approved and investigational oncology drugs described previously73.
Composition of this customized drug panel includes 45 FDA-approved drugs while
~80% of the remaining compounds have been tested in early phase clinical trials.
These drugs encompass a broad range of activities and target classes and include
inhibitors of EGFR (n= 2), FLT3 (5), PI3K/AKT/mTOR (25), MEK/ERK (7),
histone deacetylases (5), Bcl2 (3), NF-κB (2), Jak/Stats (2), PARPs (3), CDKs (7),
HSP90 (2), CHKs (4), polo-like kinases (2), aurora kinases (2), hedgehogs (3), PKC
(3), farnesyl transferases (2), GSK3 (2), proteosome components (1), additional
kinases (29), retinoids (3), and drugs that act on other or unknown targets (12),
and >80% have been tested in early phase clinical trials. Cells were seeded onto
tissue culture-treated 384-well plates that were previously prepared by a Ghosting
Protocol74 where all cellular manipulations were performed on a BioTek EL406
liquid handler. Wells of the 384-well plate were coated with Matrigel (Corning) per
the manufacturer’s recommended procedure and kept at room temperature at least
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15 min prior to the addition of MEF. For naïve cells, 386-well plates in triplicate
were seeded with γ-irradiated MEF. The feeder layer was allowed to adhere
overnight. The next day feeder extracellular matrix was generated through lysis74.
Two thousand Elf1 naïve cells per well were seeded the same day onto the extra-
cellular matrix in MEF conditioned hESC medium (supplemented with 2iL-I-F or
FGF; naïve and primed, respectively) and 4000 cells per well Elf1 primed cells were
also seeded in triplicate and both naïve and primed allowed to adhere overnight at
37 °C, 5% CO2 in 50 μl volume. After 24 h incubation at 37 °C, 5% CO2, media was
replaced with fresh media. Immediately following the media exchange, compounds
(50 nl) were added at concentrations ranging from 5 pM to 100 μM using the
CyBio CyBi-Well Vario and incubated at 37 °C, 5% CO2 for 72 h and viability was
assessed using CellTiter Glo (Promega) with quantitation of luminescence derived
from intracellular ATP. Resulting dose curves were ﬁtted to a 4 Parameter Logistic
Dose Response Model using idbs’ XLFit. CellTiter-Glo (Promega) is dispensed into
the individual wells with the WellMate and following 20 min incubation on an
orbital shaker, luminescence is measured on a Perkin Elmer EnVision Multi-label
plate reader. Percentage cell viability is reported as relative to the DMSO solvent
control. After 4 days, the results were obtained. IC50 values were calculated by
ﬁtting data using least-squares method to the standard four-parameter logistic
model where: Y= (Ymin+ (Ymax/(1+ ((X/IC50)Slope), and Y=% viability, Ymin=
minimal % viability, Ymax=maximal % viability, X= compound concentration,
IC50= concentration of compound exhibiting 50% inhibition of cellular viability,
Slope= the slope of the resultant curve. Curve ﬁtting was performed using idbs
XLFit software, an Addin for Microsoft Excel. Subsequent analysis was performed
using Tibco’s Spotﬁre software.
Reproducibility of experiments. The number of independent experiments for
each ﬁgure panel is described in the corresponding ﬁgure legend and primary data
are available in Supplementary Data 7. For all western blots presented in the
manuscript, there were at least three independent experiments.
There is no estimate of variation in each group of data and the variance is
similar between the groups. No statistical method was used to predetermine sample
size. The experiments were not randomized. The investigators were not blinded to
allocation during experiments and outcome assessment. RNA samples with 260
nm/280 nm < 1.80 were discarded.
Data availability
RNA-seq and ChIP-seq data sets generated for this study are available from the
NCBI GEO database under accession number GSE122118. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE75 partner repository with the dataset identiﬁer PXD011736. A reporting
summary is available as a Supplementary File. The source data underlying
Figs. 1e–g, 2c, g, h, 3d–f, g, i–k, 4e, g, h, k, l, 5b–g and Supplementary Figs. 3B, 4D,
4J, 4L, 5B–C, 7A are provided as a Source Data ﬁle.
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